Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Endurance Expects To Price IPO In Range Of $14 And $16 Per Share

RELATED NEWS
Trade EIGI now with 

Edurance international group said it expects to sell 23.4 million shares in a range of $14 and $16 per share in its initial public offering.

The Burlington, Massachusetts-based company said it has applied for listing of its common stock on the Nasdaq Global Market under the symbol under the symbol "EIGI".

The company, which was founded in 1997, expects to report net loss in a range of $28.9 million-$30 million and revenue to be in a range of $130 million-$131 million for the three months period ended Septemebr 30, 2013.

The communications infrastructure company expects to generate as much as $430.4 million in proceeds and those will be used to repay $286.3 million in debt and satisfy obligations related to its acquisition of Directi Web Technology Pvt. Ltd., as well as for general corporate purposes.

The company said that on December 22, 2011, investment funds and entities affiliated with either Warburg Pincus or Goldman Sachs acquired a controlling interest.

Goldman Sachs, Credit Suisse and Morgan Stanley are the joint bookrunners on the deal.

Click here to receive FREE breaking news email alerts for Endurance International Holdings and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Proctor and Gamble (PG) has sold two of its soap brands to European consumer products giant Unilever (UN). Cincinnati-based P&G says the sale includes the global Camay brand, the Zest brand outside of North America and its Talisman manufacturing plant in Mexico. The plant employs approximately... Dish Network is no longer carrying Fox News in yet another dispute for the television provider. Fox News, which changed the face of cable news with its ardent advocacy of conservative issues, went dark Sunday, replaced on Dish by The Blaze, Glen Beck's new right-leaning channel. Fox Business channel... Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.